Doximity (DOCS) Q3 2025 Earnings Call February 07, 2025 02:14 AM ET Company Participants Perry Gold - VP-IRJeff Tangney - Co-Founder and CEOAnna Bryson - CFOBrian Peterson - Managing DirectorGlen Santangelo - Managing DirectorRyan Daniels - Group Head–Healthcare Technology and ServicesRichard Close - Managing DirectorScott Schoenhaus - Managing DirectorNate Gross - Co-Founder & Chief Strategy OfficerAnne Samuel - Executive DirectorJeff Garro - Managing DirectorDavid Roman - Managing DirectorJailendra Singh ...

Doximity, Inc. (NYSE:DOCS) Q3 2025 Earnings Conference Call February 6, 2025 5:00 PM ET Company Participants Perry Gold - Vice President of Investor Relations Jeff Tangney - Co-Founder and Chief executive Officer Nate Gross - Co-Founder and Chief Strategy Officer Anna Bryson - Chief Financial Officer Conference Call Participants Brian Peterson - Raymond James Glen Santangelo - Jefferies Ryan Daniels - William Blair Ryan MacDonald - Needham & Company Elizabeth Anderson - Evercore ISI Richard Close - Canaccor ...

INVESTOR PRESENTATION Winter 2025 LEGAL DISCLAIMER This presentation and associated commentary may contain forward-looking statements, including statements regarding expectations of future results of operations or financial performance of Doximity, market size and growth opportunities, the calculation of certain of our key financial and operating metrics, capital expenditures, plans for future operations, competitive position, technological capabilities, and strategic relationships, general business conditi ...

Company Performance - Doximity reported quarterly earnings of $0.45 per share, exceeding the Zacks Consensus Estimate of $0.33 per share, and up from $0.29 per share a year ago, representing an earnings surprise of 36.36% [1] - The company posted revenues of $168.6 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 10.60%, compared to $135.28 million in the same quarter last year [2] - Doximity has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Stock Performance - Doximity shares have increased approximately 8.9% since the beginning of the year, outperforming the S&P 500's gain of 3.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.22 on revenues of $123.88 million, and for the current fiscal year, it is $1.14 on revenues of $539.15 million [7] - The estimate revisions trend for Doximity is mixed, and future earnings expectations will be influenced by management's commentary during the earnings call [3][4] Industry Context - The Medical Services industry, to which Doximity belongs, is currently ranked in the bottom 34% of over 250 Zacks industries, which may impact stock performance [8] - Another company in the same industry, NeueHealth, is expected to report a quarterly loss of $2.29 per share, indicating challenges within the sector [9]

Doximity at the New York Stock Exchange for their IPO, June 24, 2021.Shares of Doximity popped 21% on Thursday after the company reported third-quarter fiscal 2025 results that beat analysts' expectations for revenue and offered rosy guidance.Here's how the company did:Earnings per share: 37 cents. That may not compare with the 34 cents expected by LSEG.Revenue: $168.6 million vs. $152.8 million expected by LSEG.Doximity is a digital platform for medical professionals that helps clinicians stay current on m ...

Doximity exceeded expectations with strong revenue and net income growth, highlighting robust operational performance.Doximity (DOCS), a digital platform for U.S. medical professionals, released its fiscal third-quarter earnings on Feb. 6, 2025. The company reported impressive results, surpassing both analyst forecasts and its own guidance. It achieved a non-GAAP earnings per share (EPS) of $0.45, well above the estimate of $0.34. Revenue reached $168.6 million, compared to expectations of $152 million. Ove ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q _________________________________________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 500 3rd St. OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Suite 510 For the transition period from to ...

Exhibit 99.1 Doximity Announces Fiscal 2025 Third Quarter Financial Results Total revenues of $168.6 million, up 25% year-over-year Net income growth of 57% and adjusted EBITDA growth of 39% year-over-year SAN FRANCISCO, Calif., February 6, 2025 -- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2025 third quarter ended December 31, 2024. "We're proud to deliver another quarter of record engagement in Q3, with over 610,000 uniqu ...

For Immediate ReleasesChicago, IL – January 23, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include, Doximity (DOCS) , Omnicell (OMCL) , Embecta Corp. (EMBC) , Cencora, Inc. (COR) and the Global Telemedicine & Digital Health ETF (EDOC) .Here are highlights from Thursday’s Analyst Blog:4 MedTech Stocks Poised to Thrive ...

Investment Analysis - The analyst recommended a hold rating for Doximity (NYSE: DOCS) on 2nd October last year, as the valuation was believed to have already priced in near-term upside [1] - An ideal investment is considered to be one that operates in a sector projected to experience structural (organic) growth exceeding GDP growth over the next 5-10 years [1] - The investment should also profit from sustainable competitive advantages that translate into attractive unit economics [1] - The company should be managed by competent, ethical, and long-term thinkers [1] - The valuation of the investment should be fair [1]